What predicts cognitive decline in de novo Parkinson's disease?

Dario Arnaldi, Claudio Campus, Michela Ferrara, Francesco Famà, Agnese Picco, Fabrizio De Carli, Jennifer Accardo, Andrea Brugnolo, Gianmario Sambuceti, Silvia Morbelli, Flavio Nobili

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Subtle cognitive impairment can be detected in early Parkinson's disease (PD). In a consecutive series of de novo, drug-naive PD patients, we applied stepwise regression analysis to assess which clinical, neuropsychological, and functional neuroimaging (dopamine transporter [DAT] and perfusion single photon emission computed tomography [SPECT]) characteristics at baseline was predictive of cognitive decline during an average follow-up time of about 4 years. Decline both in executive (R2 = 0.54; p = 0.0001) and visuospatial (R2 = 0.56; p = 0.0001) functions was predicted by the couple of Unified Parkinson's Disease Rating Scale (UPDRS)-III score and caudate dopamine transporter (DAT) uptake in the less affected hemisphere (LAH). Verbal memory and language decline was predicted instead by caudate DAT uptake and brain perfusion in a posterior parieto-temporal area of the less affected hemisphere (R2 = 0.42; p = 0.0005). No significant effect was shown for age, baseline neuropsychological scores, and levodopa equivalent dose at follow-up. The combined use of clinical structured examination and brain functional assessment by means of dual single photon emission computed tomography imaging appears as a powerful approach to predict cognitive decline in de novo PD patients.

Original languageEnglish
JournalNeurobiology of Aging
Volume33
Issue number6
DOIs
Publication statusPublished - Jun 2012

Fingerprint

Dopamine Plasma Membrane Transport Proteins
Parkinson Disease
Single-Photon Emission-Computed Tomography
Perfusion
Functional Neuroimaging
Brain
Levodopa
Language
Regression Analysis
Cognitive Dysfunction
Pharmaceutical Preparations

Keywords

  • Cognitive decline
  • Dopamine transporter SPECT
  • Neuropsychological tests
  • Parkinson's disease
  • Perfusion SPECT

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)
  • Ageing
  • Developmental Biology
  • Geriatrics and Gerontology

Cite this

Arnaldi, D., Campus, C., Ferrara, M., Famà, F., Picco, A., De Carli, F., ... Nobili, F. (2012). What predicts cognitive decline in de novo Parkinson's disease? Neurobiology of Aging, 33(6). https://doi.org/10.1016/j.neurobiolaging.2011.11.028

What predicts cognitive decline in de novo Parkinson's disease? / Arnaldi, Dario; Campus, Claudio; Ferrara, Michela; Famà, Francesco; Picco, Agnese; De Carli, Fabrizio; Accardo, Jennifer; Brugnolo, Andrea; Sambuceti, Gianmario; Morbelli, Silvia; Nobili, Flavio.

In: Neurobiology of Aging, Vol. 33, No. 6, 06.2012.

Research output: Contribution to journalArticle

Arnaldi, D, Campus, C, Ferrara, M, Famà, F, Picco, A, De Carli, F, Accardo, J, Brugnolo, A, Sambuceti, G, Morbelli, S & Nobili, F 2012, 'What predicts cognitive decline in de novo Parkinson's disease?', Neurobiology of Aging, vol. 33, no. 6. https://doi.org/10.1016/j.neurobiolaging.2011.11.028
Arnaldi, Dario ; Campus, Claudio ; Ferrara, Michela ; Famà, Francesco ; Picco, Agnese ; De Carli, Fabrizio ; Accardo, Jennifer ; Brugnolo, Andrea ; Sambuceti, Gianmario ; Morbelli, Silvia ; Nobili, Flavio. / What predicts cognitive decline in de novo Parkinson's disease?. In: Neurobiology of Aging. 2012 ; Vol. 33, No. 6.
@article{ed6b619b5bea459eaa9132f5c5c378e9,
title = "What predicts cognitive decline in de novo Parkinson's disease?",
abstract = "Subtle cognitive impairment can be detected in early Parkinson's disease (PD). In a consecutive series of de novo, drug-naive PD patients, we applied stepwise regression analysis to assess which clinical, neuropsychological, and functional neuroimaging (dopamine transporter [DAT] and perfusion single photon emission computed tomography [SPECT]) characteristics at baseline was predictive of cognitive decline during an average follow-up time of about 4 years. Decline both in executive (R2 = 0.54; p = 0.0001) and visuospatial (R2 = 0.56; p = 0.0001) functions was predicted by the couple of Unified Parkinson's Disease Rating Scale (UPDRS)-III score and caudate dopamine transporter (DAT) uptake in the less affected hemisphere (LAH). Verbal memory and language decline was predicted instead by caudate DAT uptake and brain perfusion in a posterior parieto-temporal area of the less affected hemisphere (R2 = 0.42; p = 0.0005). No significant effect was shown for age, baseline neuropsychological scores, and levodopa equivalent dose at follow-up. The combined use of clinical structured examination and brain functional assessment by means of dual single photon emission computed tomography imaging appears as a powerful approach to predict cognitive decline in de novo PD patients.",
keywords = "Cognitive decline, Dopamine transporter SPECT, Neuropsychological tests, Parkinson's disease, Perfusion SPECT",
author = "Dario Arnaldi and Claudio Campus and Michela Ferrara and Francesco Fam{\`a} and Agnese Picco and {De Carli}, Fabrizio and Jennifer Accardo and Andrea Brugnolo and Gianmario Sambuceti and Silvia Morbelli and Flavio Nobili",
year = "2012",
month = "6",
doi = "10.1016/j.neurobiolaging.2011.11.028",
language = "English",
volume = "33",
journal = "Neurobiology of Aging",
issn = "0197-4580",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - What predicts cognitive decline in de novo Parkinson's disease?

AU - Arnaldi, Dario

AU - Campus, Claudio

AU - Ferrara, Michela

AU - Famà, Francesco

AU - Picco, Agnese

AU - De Carli, Fabrizio

AU - Accardo, Jennifer

AU - Brugnolo, Andrea

AU - Sambuceti, Gianmario

AU - Morbelli, Silvia

AU - Nobili, Flavio

PY - 2012/6

Y1 - 2012/6

N2 - Subtle cognitive impairment can be detected in early Parkinson's disease (PD). In a consecutive series of de novo, drug-naive PD patients, we applied stepwise regression analysis to assess which clinical, neuropsychological, and functional neuroimaging (dopamine transporter [DAT] and perfusion single photon emission computed tomography [SPECT]) characteristics at baseline was predictive of cognitive decline during an average follow-up time of about 4 years. Decline both in executive (R2 = 0.54; p = 0.0001) and visuospatial (R2 = 0.56; p = 0.0001) functions was predicted by the couple of Unified Parkinson's Disease Rating Scale (UPDRS)-III score and caudate dopamine transporter (DAT) uptake in the less affected hemisphere (LAH). Verbal memory and language decline was predicted instead by caudate DAT uptake and brain perfusion in a posterior parieto-temporal area of the less affected hemisphere (R2 = 0.42; p = 0.0005). No significant effect was shown for age, baseline neuropsychological scores, and levodopa equivalent dose at follow-up. The combined use of clinical structured examination and brain functional assessment by means of dual single photon emission computed tomography imaging appears as a powerful approach to predict cognitive decline in de novo PD patients.

AB - Subtle cognitive impairment can be detected in early Parkinson's disease (PD). In a consecutive series of de novo, drug-naive PD patients, we applied stepwise regression analysis to assess which clinical, neuropsychological, and functional neuroimaging (dopamine transporter [DAT] and perfusion single photon emission computed tomography [SPECT]) characteristics at baseline was predictive of cognitive decline during an average follow-up time of about 4 years. Decline both in executive (R2 = 0.54; p = 0.0001) and visuospatial (R2 = 0.56; p = 0.0001) functions was predicted by the couple of Unified Parkinson's Disease Rating Scale (UPDRS)-III score and caudate dopamine transporter (DAT) uptake in the less affected hemisphere (LAH). Verbal memory and language decline was predicted instead by caudate DAT uptake and brain perfusion in a posterior parieto-temporal area of the less affected hemisphere (R2 = 0.42; p = 0.0005). No significant effect was shown for age, baseline neuropsychological scores, and levodopa equivalent dose at follow-up. The combined use of clinical structured examination and brain functional assessment by means of dual single photon emission computed tomography imaging appears as a powerful approach to predict cognitive decline in de novo PD patients.

KW - Cognitive decline

KW - Dopamine transporter SPECT

KW - Neuropsychological tests

KW - Parkinson's disease

KW - Perfusion SPECT

UR - http://www.scopus.com/inward/record.url?scp=84859492737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859492737&partnerID=8YFLogxK

U2 - 10.1016/j.neurobiolaging.2011.11.028

DO - 10.1016/j.neurobiolaging.2011.11.028

M3 - Article

VL - 33

JO - Neurobiology of Aging

JF - Neurobiology of Aging

SN - 0197-4580

IS - 6

ER -